Atom Therapeutics (Atom Therapeutics Co., Ltd ) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout, acute gout and others for which there are no effective treatments.

Atom’s lead product, ABP-671, is in multicenter Phase 2b/3 clinical trials worldwide, including the US, for treatment of chronic gout. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs.

Another small molecule, ABP-745, has shown significant efficacy and good safety in animal models of anti-inflammation. ABP-745 has also demonstrated safety and efficacy in pre-clinical trials for acute gout and other anti-inflammation diseases and is in Phase 1 clinical trials.

Latest News from Atom Therapeutics

12 November, 2024
Atom Therapeutics to Present Positive Data from a Phase 1 Trial of Its Novel URAT1 Inhibitor for Chronic Gout (ABP-671) in Participants with Chronic Kidney Disease at ACR Convergence 2024
12 November, 2024
Atom Bioscience Changes Name to Atom Therapeutics To Better Reflect Focus on Development of Best-in-Class Novel Oral Drugs for Inflammatory and Metabolic Diseases
21 May, 2024
Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout
24 April, 2024
Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout
More Atom News